Heart surgery shock drug trial stalls after just two patients
NCT ID NCT04904562
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested angiotensin II (Giapreza) as a first-line treatment for distributive shock in patients who had a heart transplant or LVAD implant. The goal was to see if it could reduce the need for other blood pressure medications. However, the trial was terminated early after enrolling only 2 out of 40 planned participants, so no meaningful conclusions can be drawn.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Angiotensin II (Giapreza)
What this could lead to
If successful, this could point toward a new first-line treatment for shock after heart surgery, potentially reducing the need for other strong medications.
What could go wrong
This was a very small pilot study that ended early with only 2 participants, so results are not reliable. The drug may not work better than standard care, and side effects are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DISTRIBUTIVE SHOCK are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Northwestern University
Chicago, Illinois, 60611, United States